Xenetic Biosciences(DE:3XB0)
€3.860.00 (0.00%)
DE:3XB0
Xenetic Biosciences financials statements
€3.86
At close:0.00 (0.00%)
Xenetic Biosciences (3XB0) Ratios
0 Followers
Xenetic Biosciences Ratios
DE:3XB0's free cash flow for Q3 2026 was $-662.13K. For the 2026 fiscal year, DE:3XB0's free cash flow was increased by $0.00 and operating cash flow was $-662.13K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.32 | 7.37 | 11.84 | 12.72 | 13.18 |
| Quick Ratio | 8.32 | 7.37 | 11.84 | 12.72 | 13.18 |
| Cash Ratio | 8.14 | 6.89 | 11.10 | 12.20 | 12.84 |
| Solvency Ratio | -2.77 | -4.26 | -5.11 | -6.08 | -3.95 |
| Operating Cash Flow Ratio | -2.36 | -3.15 | -5.08 | -4.33 | -3.33 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 7.08M | $ 5.69M | $ 8.78M | $ 12.58M | $ 17.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.15 | 1.08 | 1.08 | 1.08 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Net Debt to EBITDA | 2.94 | 1.62 | 1.99 | 1.96 | 3.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -90.07% | -158.39% | -177.79% | -393.57% | -495.12% |
| EBITDA Margin | -90.07% | -152.26% | -177.79% | -391.98% | -492.06% |
| Operating Profit Margin | -95.23% | -168.16% | -177.79% | -393.57% | -495.12% |
| Pretax Profit Margin | -90.07% | -158.39% | -162.78% | -383.87% | -486.36% |
| Net Profit Margin | -90.07% | -158.39% | -162.78% | -383.87% | -486.36% |
| Continuous Operations Profit Margin | -90.07% | -158.39% | -162.78% | -383.87% | -486.36% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.58% | 94.19% | 91.56% | 97.54% | 98.23% |
| Return on Assets (ROA) | -32.05% | -57.38% | -38.99% | -44.51% | -28.49% |
| Return on Equity (ROE) | -36.25% | -65.93% | -42.21% | -48.01% | -30.69% |
| Return on Capital Employed (ROCE) | -38.33% | -69.99% | -46.10% | -49.23% | -31.24% |
| Return on Invested Capital (ROIC) | -38.33% | -69.99% | -46.10% | -49.23% | -31.20% |
| Return on Tangible Assets | -32.05% | -57.38% | -38.99% | -44.51% | -28.49% |
| Earnings Yield | -72.60% | -64.40% | -78.42% | -161.63% | -42.57% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.36 | 0.36 | 0.24 | 0.12 | 0.06 |
| Working Capital Turnover Ratio | 0.47 | 0.35 | 0.24 | 0.11 | 0.08 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.34 | -1.83 | -2.69 | -3.27 | -4.61 |
| Free Cash Flow Per Share | -1.34 | -1.83 | -2.69 | -3.62 | -4.61 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -4114219.00 | -9.29 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -4114219.00 | -9.29 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -175.20 |
| Operating Cash Flow to Sales Ratio | -0.77 | -1.13 | -1.62 | -2.72 | -4.08 |
| Free Cash Flow Yield | -61.93% | -45.81% | -78.03% | -126.96% | -35.73% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.37 | -1.55 | -1.28 | -0.62 | -2.35 |
| Price-to-Sales (P/S) Ratio | 1.24 | 2.46 | 2.08 | 2.38 | 11.42 |
| Price-to-Book (P/B) Ratio | 0.50 | 1.02 | 0.54 | 0.30 | 0.72 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.61 | -2.18 | -1.28 | -0.79 | -2.80 |
| Price-to-Operating Cash Flow Ratio | -1.61 | -2.18 | -1.28 | -0.87 | -2.80 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.30 | 0.03 | 0.04 | 0.03 |
| Enterprise Value Multiple | 1.56 | 0.00 | 0.82 | 1.35 | 0.87 |
| Enterprise Value | -4.19M | -15.63K | -3.71M | -9.04M | -4.96M |
| EV to EBITDA | 1.56 | 0.00 | 0.82 | 1.35 | 0.87 |
| EV to Sales | -1.41 | -0.01 | -1.46 | -5.30 | -4.27 |
| EV to Free Cash Flow | 1.83 | 0.01 | 0.90 | 1.76 | 1.05 |
| EV to Operating Cash Flow | 1.83 | 0.01 | 0.90 | 1.95 | 1.05 |
| Tangible Book Value Per Share | 4.35 | 3.90 | 6.41 | 9.59 | 17.89 |
| Shareholders’ Equity Per Share | 4.35 | 3.90 | 6.41 | 9.59 | 17.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.75 | 1.62 | 1.66 | 1.20 | 1.13 |
| Net Income Per Share | -1.58 | -2.57 | -2.71 | -4.61 | -5.49 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.92 | 0.98 | 0.98 |
| Research & Development to Revenue | 1.03 | 1.32 | 1.38 | 2.79 | 2.73 |
| SG&A to Revenue | 0.92 | 1.37 | 1.40 | 2.14 | 3.23 |
| Stock-Based Compensation to Revenue | 0.02 | 0.07 | 0.11 | 0.30 | 0.35 |
| Income Quality | 0.85 | 0.71 | 1.00 | 0.71 | 0.84 |
Currency in USD

